Placeholder Banner

Trubion reports positive data from Phase 2B TRU-015 study

October 19, 2009
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA.

Trubion’s President and CEO, Dr. Peter A. Thompson, will be a panelist at BIO Investor Forum’s “Resisting the Enemy Within - Keeping Score on the War Against Autoimmune Disease” Therapeutic Workshop.